PE20230832A1 - Compuestos de insulina acilada de accion temporal prolongada - Google Patents

Compuestos de insulina acilada de accion temporal prolongada

Info

Publication number
PE20230832A1
PE20230832A1 PE2022002656A PE2022002656A PE20230832A1 PE 20230832 A1 PE20230832 A1 PE 20230832A1 PE 2022002656 A PE2022002656 A PE 2022002656A PE 2022002656 A PE2022002656 A PE 2022002656A PE 20230832 A1 PE20230832 A1 PE 20230832A1
Authority
PE
Peru
Prior art keywords
long
lys
acylated insulin
insulin compounds
compounds
Prior art date
Application number
PE2022002656A
Other languages
English (en)
Inventor
Seamus Patrick Brennan
David Benjamin Flora
Valdislav Kisselev
Wen Liu
Francisco Alcides VALENZUELA
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20230832A1 publication Critical patent/PE20230832A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La invencion se refiere a compuestos de insulina acilada de accion temporal prolongada de formula (I); en donde X se selecciona del grupo que consiste en -Lys-Gly-, -Lys-(acido 2-[2-(2-aminoetoxi)etoxi]acetico)- y -Lys-Gly-; o una sal farmaceuticamente aceptable del mismo. Dichos compuestos tienen una tasa de depuracion mas lenta que las insulinas aciladas conocidas, biodisponibilidad mejorada, un perfil farmacocinetico mas estable en y/o una mayor duracion de la accion del compuesto in vivo. Tambien refiere a una composicion farmaceutica que comprende el compuesto de formula (I); siendo util para el tratamiento de la diabetes tipo I y/o tipo II y/o la hiperglucemia.
PE2022002656A 2020-05-15 2021-05-13 Compuestos de insulina acilada de accion temporal prolongada PE20230832A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063025463P 2020-05-15 2020-05-15
PCT/US2021/032144 WO2021231676A1 (en) 2020-05-15 2021-05-13 Extended time action acylated insulin compounds

Publications (1)

Publication Number Publication Date
PE20230832A1 true PE20230832A1 (es) 2023-05-19

Family

ID=78524979

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022002656A PE20230832A1 (es) 2020-05-15 2021-05-13 Compuestos de insulina acilada de accion temporal prolongada

Country Status (16)

Country Link
US (1) US20230174609A1 (es)
EP (1) EP4149516A1 (es)
JP (1) JP7456007B2 (es)
KR (1) KR20230009499A (es)
CN (1) CN115867308A (es)
AU (1) AU2021273262A1 (es)
BR (1) BR112022022885A2 (es)
CA (1) CA3177905A1 (es)
CL (1) CL2022003187A1 (es)
CO (1) CO2022016338A2 (es)
CR (1) CR20220641A (es)
EC (1) ECSP22087958A (es)
IL (1) IL297976A (es)
MX (1) MX2022014309A (es)
PE (1) PE20230832A1 (es)
WO (1) WO2021231676A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116162147B (zh) * 2021-11-24 2023-10-03 成都奥达生物科技有限公司 一种长效胰岛素类似物
CN115850385B (zh) * 2022-07-04 2023-08-11 北京惠之衡生物科技有限公司 一种促表达肽及其应用
CN115894719B (zh) * 2022-11-24 2023-10-20 武汉禾元生物科技股份有限公司 一种人血清白蛋白胰岛素偶联物及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US6444641B1 (en) * 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
HUP0004169A3 (en) 1997-10-24 2001-06-28 Lilly Co Eli Insoluble insulin compositions and process for production thereof
WO2017005765A1 (en) 2015-07-06 2017-01-12 Novo Nordisk A/S Novel peptides and peptide derivatives and uses thereof
JOP20190273A1 (ar) 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل

Also Published As

Publication number Publication date
JP7456007B2 (ja) 2024-03-26
CO2022016338A2 (es) 2022-11-29
KR20230009499A (ko) 2023-01-17
MX2022014309A (es) 2022-12-07
AU2021273262A1 (en) 2022-12-08
IL297976A (en) 2023-01-01
EP4149516A1 (en) 2023-03-22
CL2022003187A1 (es) 2023-03-03
CR20220641A (es) 2023-01-19
JP2023526069A (ja) 2023-06-20
ECSP22087958A (es) 2022-12-30
CA3177905A1 (en) 2021-11-18
CN115867308A (zh) 2023-03-28
WO2021231676A1 (en) 2021-11-18
US20230174609A1 (en) 2023-06-08
BR112022022885A2 (pt) 2022-12-20

Similar Documents

Publication Publication Date Title
PE20230832A1 (es) Compuestos de insulina acilada de accion temporal prolongada
US9872845B2 (en) Methods of treating myeloma and lymphoma using compositions containing an ion pair of a lipoic acid derivative
AU2017298142B2 (en) Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia
RU2007124686A (ru) Биарилоксиметилареновые карбоновые кислоты
DK2544536T3 (en) FAT ACID CONJUGATES OF QUETIAPIN, METHOD OF PREPARING IT AND USING IT
RU2518483C2 (ru) Режим дозирования ингибиторов комт
RU2013107748A (ru) Производные с-арилглюкозидов, способ их получения и фармацевтическое применение
UA82831C2 (uk) Сполуки для лікування розладів обміну речовин
AU2014207408C1 (en) Pharmaceutical compositions comprising nitroxyl donors
JP2012520342A5 (es)
MX367769B (es) Nuevo derivado de acido 3-(4-(benciloxi)fenil)hex-4-inoico, metodo de preparacion del mismo y composicion farmaceutica para la prevencion y tratamiento de la enfermedad metabolica que incluye el mismo como ingrediente activo.
JP2008530242A5 (es)
WO2020185881A1 (en) Charged ion channel blockers and methods for use
RU2017109814A (ru) Кристаллическая 7-{ (3s,4s)-3-[(циклопропиламино)метил]-4-фторпирролидин-1-ил} -6-фтор-1-(2-фторэтил)-8-метокси-4-оксо-1,4-дигидрохинолин-3-карбоновая кислота
KR20180093932A (ko) 창상 치료제
US9670236B2 (en) Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury
US20180312455A1 (en) Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury
KR20230022830A (ko) 하전된 이온 채널 차단제 및 사용 방법
KR20140137681A (ko) N1-고리아민-n5-치환된 바이구아나이드 유도체를 유효성분으로 함유하는 섬유화 예방 또는 치료용 약학 조성물
RU2014132837A (ru) Конъюгаты антагонистов интегрина для нацеленной доставки к клеткам, экспрессирующим lfa-1
US20210309623A1 (en) Charged ion channel blockers and methods for use
US20100035996A1 (en) Glucose metabolism stimulating agent
DK144822B (da) Analogifremgangsmaade til fremstilling af hoejredrejende 7-brom-6-chlor-3-(3-(3-hydroxy-2-peperidyl)-acetonyl)-4-3h-quinazolinon eller dets additionssalte med syrer
CA3101977A1 (en) Novel hif-1-alpha inhibitor, method of preparing the same, and pharmaceutical composition for preventing or treating angiogenesis-related eye disease containing the same as active ingredient
JP2017530182A5 (es)